Merus (MRUS)
(Delayed Data from NSDQ)
$52.90 USD
-0.81 (-1.51%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $52.92 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Merus N.V. [MRUS]
Reports for Purchase
Showing records 121 - 140 ( 174 total )
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
3Q19: T-Cell Engager Data in 1H20 Could Be a Value Driver
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
CD137 Bispecific Antibody Kills Tumors in Mice
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
NRG1 Fusion Focus for MCLA-128 Ultimately a Positive
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Refocusing Efforts in NRG1 Fusion - Positive Solid Tumors
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
SITC Is Only 33 Days Away: Abstract Titles Released
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Biotechnology - ESMO 2019 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Elevating the Game with Multiple Escalation Studies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
2Q19 - T-Cell Engager Shows Early Signs of Activity
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Initiating at Buy with $20 PT.
Provider: Roth Capital Partners, Inc.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
1Q19 Financials; Multiple Updates Coming in H2
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Biotechnology - AACR Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
4Q18 Financials; Early-Stage Biclonics Programs Hold Significant Promise
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.